JP2011500819A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500819A5
JP2011500819A5 JP2010531141A JP2010531141A JP2011500819A5 JP 2011500819 A5 JP2011500819 A5 JP 2011500819A5 JP 2010531141 A JP2010531141 A JP 2010531141A JP 2010531141 A JP2010531141 A JP 2010531141A JP 2011500819 A5 JP2011500819 A5 JP 2011500819A5
Authority
JP
Japan
Prior art keywords
formulation
disease
diseases
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010531141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/080256 external-priority patent/WO2009055308A1/en
Publication of JP2011500819A publication Critical patent/JP2011500819A/ja
Publication of JP2011500819A5 publication Critical patent/JP2011500819A5/ja
Withdrawn legal-status Critical Current

Links

JP2010531141A 2007-10-24 2008-10-17 アリルインデノピリミジン及びアデノシンA2a受容体拮抗物質としてのそれらの使用 Withdrawn JP2011500819A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98224707P 2007-10-24 2007-10-24
PCT/US2008/080256 WO2009055308A1 (en) 2007-10-24 2008-10-17 Arylindenopyrimidines and their use as adenosine a2a receptor antagonists

Publications (2)

Publication Number Publication Date
JP2011500819A JP2011500819A (ja) 2011-01-06
JP2011500819A5 true JP2011500819A5 (https=) 2012-12-20

Family

ID=40091927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010531141A Withdrawn JP2011500819A (ja) 2007-10-24 2008-10-17 アリルインデノピリミジン及びアデノシンA2a受容体拮抗物質としてのそれらの使用

Country Status (12)

Country Link
US (1) US8017614B2 (https=)
EP (1) EP2217575A1 (https=)
JP (1) JP2011500819A (https=)
CN (1) CN101835759A (https=)
AR (1) AR069009A1 (https=)
AU (1) AU2008317034A1 (https=)
CL (1) CL2008003131A1 (https=)
PA (1) PA8801501A1 (https=)
PE (1) PE20091344A1 (https=)
TW (1) TW200934493A (https=)
UY (1) UY31420A1 (https=)
WO (1) WO2009055308A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
GB2497476B (en) 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
KR20140146217A (ko) 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド Trop-2発現がんを治療するための併用療法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
EP1673354B1 (en) 2003-10-03 2009-04-22 Ortho-McNeil Pharmaceutical, Inc. Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists

Similar Documents

Publication Publication Date Title
CN102046176B (zh) 5-ht3受体调节剂、其制备方法和用途
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
TW200829244A (en) Therapeutic combinations 482
JP2011500819A5 (https=)
JP2019503365A5 (https=)
US20230250076A1 (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
JP2013516497A (ja) 認知増強のための化合物と組成物、製造方法、および治療方法
JP2015514135A5 (https=)
JP2011068653A5 (https=)
JP2014517050A5 (https=)
CN103172628A (zh) (2s,3r)-n-(2-((3-吡啶基)甲基)-1-氮杂双环[2.2.2]辛-3-基)苯并呋喃-2-甲酰胺、其新的盐形式和用法
JP2005537268A5 (https=)
JP2015509972A5 (https=)
JP2012508734A5 (https=)
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
JP2007533687A (ja) 月経前の及び他の女性の性的障害の治療におけるフリバンセリンの使用
JP2012519704A (ja) 認知増強用化合物及び組成物、製造法、並びに治療法
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
TWI804687B (zh) 慢性咳嗽治療用醫藥
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
SI3029039T1 (en) Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate
JP2011516588A5 (https=)
CA3102762A1 (en) Eaat2 activators and methods of using thereof
CN116940362A (zh) 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性